| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC2642 |
| Trial ID | NCT04832724 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | RGX-314 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered Via Subretinal Delivery in Participants With Neovascular Age-related Macular Degeneration |
| Year | 2021 |
| Country | United States |
| Company sponsor | AbbVie |
| Other ID(s) | RGX-314-2103 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||